Bayesian optimal interval designs for phase I clinical trials

Citations Over TimeTop 10% of 2014 papers

Abstract

In phase I trials, effectively treating patients and minimizing the chance of exposing them to subtherapeutic and overly toxic doses are clinicians' top priority. Motived by this practical consideration, we propose Bayesian optimal interval (BOIN) designs to find the maximum tolerated dose and to minimize the probability of inappropriate dose assignments for patients. We show, both theoretically and numerically, that the BOIN design not only has superior finite and large sample properties but also can be easily implemented in a simple way similar to the traditional ‘3+3’ design. Compared with the well-known continual reassessment method, the BOIN design yields comparable average performance to select the maximum tolerated dose but has a substantially lower risk of assigning patients to subtherapeutic and overly toxic doses. We apply the BOIN design to two cancer clinical trials.

Related Papers

• → Confidence intervals for the variance and difference of variances of Birnbaum-Saunders distributions(2022)11 cited
• → A fair comparison of credible and confidence intervals: an example with binomial proportions(2021)2 cited
• → Confidence Intervals for the Mean of Birnbaum-Saunders Distribution with Application to Wind Speed Data(2024)1 cited
• → GENERALIZED CONFIDENCE INTERVALS FOR THE PROCESS CAPABILITY INDICES(2001)
• → Confidence Intervals(2022)